These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23311002)

  • 1. [Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].
    Kim KA
    Korean J Gastroenterol; 2012 Nov; 60(5):273-4. PubMed ID: 23311002
    [No Abstract]   [Full Text] [Related]  

  • 2. Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
    Jung YK; Kim JH
    Clin Mol Hepatol; 2013 Mar; 19(1):26-8. PubMed ID: 23593606
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
    Song BC
    Korean J Gastroenterol; 2010 Jul; 56(1):59-61. PubMed ID: 20664319
    [No Abstract]   [Full Text] [Related]  

  • 4. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of peginterferon alpha-2a combinated with ribavirin in the treatment of rebound patient with chronic hepatitis C: a case report].
    He Q; Li ZY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Oct; 18(10):794. PubMed ID: 21059303
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
    Chung WJ
    Clin Mol Hepatol; 2012 Sep; 18(3):268-71. PubMed ID: 23091806
    [No Abstract]   [Full Text] [Related]  

  • 7. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 8. Peginterferon and ribavirin for hepatitis C.
    Duggan AE; Duggan JM
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17377169
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chronic C virus infection management].
    García González N; Prieto Valtueña J
    Rev Clin Esp; 2003 Sep; 203(9):443-4. PubMed ID: 14563259
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
    An J; Qiao J; Ni W
    Zhonghua Gan Zang Bing Za Zhi; 2014 Oct; 22(10):772-3. PubMed ID: 25558497
    [No Abstract]   [Full Text] [Related]  

  • 11. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Taylor LE; Rich JD; Tashima KT
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
    Hadziyannis SJ; Sevastianos V
    Aliment Pharmacol Ther; 2013 Feb; 37(4):491. PubMed ID: 23336678
    [No Abstract]   [Full Text] [Related]  

  • 13. Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Henke H; Schmiegel W; Brechmann T; Voigt E; Griga T
    J Clin Gastroenterol; 2004 Mar; 38(3):301-3. PubMed ID: 15128086
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 15. Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Aguilar Reina J
    Rev Esp Enferm Dig; 2009 Oct; 101(10):665-70. PubMed ID: 19899934
    [No Abstract]   [Full Text] [Related]  

  • 16. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Gholam PM
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].
    Park SY; Rim MY; Yo IK; Ha MS; Kim JS; Lee JW; Jung YK; Kwon OS; Kim YS; Choi DJ; Kim JH
    Korean J Gastroenterol; 2012 Nov; 60(5):306-14. PubMed ID: 23172279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
    [No Abstract]   [Full Text] [Related]  

  • 19. [Peginterferon alpha combined with ribavirin for the treatment of chronic hepatitis C].
    Xu Y; Wang JB
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jun; 19(6):415-6. PubMed ID: 22053369
    [No Abstract]   [Full Text] [Related]  

  • 20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.
    Rakov NE
    N Engl J Med; 2003 Jan; 348(3):259-60; author reply 259-60. PubMed ID: 12529472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.